Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Tao Sun et al.|New England Journal of Medicine|2022Cited by 2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Fátima Cardoso, Eric P. Winer, A. Costa et al.|Annals of Oncology|2016Cited by 2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Fátima Cardoso, Eric P. Winer, Shani Paluch–Shimon et al.|Annals of Oncology|2020Cited by 1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Giuseppe Curigliano et al.|Annals of Oncology|2021Cited by 799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724